miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release

Drug-induced liver injury (DILI) is a challenging clinical problem with respect to both diagnosis and management. As a newly emerging biomarker of liver injury, miR122 shows great potential in early and sensitive in situ detection of DILI. Glycyrrhetinic acid (GA) possesses desirable therapeutic eff...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lingchang Meng, Qiaolei Wang, Lai Wang, Zhen Zhao, Gui-Zhong Xin, Zuguo Zheng, Ping Zhou, Ping Li, Yan Jiang, Hui-Jun Li
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	miR122 All-in-one theranostic nanoplatform Drug-induced liver injury In situ detection On-demand drug release Medicine (General) R5-920 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/9f5f733cc6914f77b87c7c4ef60d5273
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f5f733cc6914f77b87c7c4ef60d5273
record_format	dspace
spelling	oai:doaj.org-article:9f5f733cc6914f77b87c7c4ef60d52732021-11-14T04:35:15ZmiR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release2590-006410.1016/j.mtbio.2021.100157https://doaj.org/article/9f5f733cc6914f77b87c7c4ef60d52732021-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S259000642100065Xhttps://doaj.org/toc/2590-0064Drug-induced liver injury (DILI) is a challenging clinical problem with respect to both diagnosis and management. As a newly emerging biomarker of liver injury, miR122 shows great potential in early and sensitive in situ detection of DILI. Glycyrrhetinic acid (GA) possesses desirable therapeutic effect on DILI, but its certain dose-dependent side effects after long-term and/or high-dose administration limit its clinical application. In this study, in order to improve the precise diagnosis and effective treatment of DILI, GA loaded all-in-one theranostic nanoplatform was designed by assembling of upconversion nanoparticles and gold nanocages. As a proof of concept, we demonstrated the applicability of this single-wavelength laser-triggered theranostic nanoplatform for the spatiotemporally controllable in situ imaging of DILI and miR122-controlled on-demand drug release in vitro and in vivo. This novel nanoplatform opens a promising avenue for the clinical diagnosis and treatment of DILI.Lingchang MengQiaolei WangLai WangZhen ZhaoGui-Zhong XinZuguo ZhengPing ZhouPing LiYan JiangHui-Jun LiElsevierarticlemiR122All-in-one theranostic nanoplatformDrug-induced liver injuryIn situ detectionOn-demand drug releaseMedicine (General)R5-920Biology (General)QH301-705.5ENMaterials Today Bio, Vol 12, Iss , Pp 100157- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	miR122 All-in-one theranostic nanoplatform Drug-induced liver injury In situ detection On-demand drug release Medicine (General) R5-920 Biology (General) QH301-705.5
spellingShingle	miR122 All-in-one theranostic nanoplatform Drug-induced liver injury In situ detection On-demand drug release Medicine (General) R5-920 Biology (General) QH301-705.5 Lingchang Meng Qiaolei Wang Lai Wang Zhen Zhao Gui-Zhong Xin Zuguo Zheng Ping Zhou Ping Li Yan Jiang Hui-Jun Li miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
description	Drug-induced liver injury (DILI) is a challenging clinical problem with respect to both diagnosis and management. As a newly emerging biomarker of liver injury, miR122 shows great potential in early and sensitive in situ detection of DILI. Glycyrrhetinic acid (GA) possesses desirable therapeutic effect on DILI, but its certain dose-dependent side effects after long-term and/or high-dose administration limit its clinical application. In this study, in order to improve the precise diagnosis and effective treatment of DILI, GA loaded all-in-one theranostic nanoplatform was designed by assembling of upconversion nanoparticles and gold nanocages. As a proof of concept, we demonstrated the applicability of this single-wavelength laser-triggered theranostic nanoplatform for the spatiotemporally controllable in situ imaging of DILI and miR122-controlled on-demand drug release in vitro and in vivo. This novel nanoplatform opens a promising avenue for the clinical diagnosis and treatment of DILI.
format	article
author	Lingchang Meng Qiaolei Wang Lai Wang Zhen Zhao Gui-Zhong Xin Zuguo Zheng Ping Zhou Ping Li Yan Jiang Hui-Jun Li
author_facet	Lingchang Meng Qiaolei Wang Lai Wang Zhen Zhao Gui-Zhong Xin Zuguo Zheng Ping Zhou Ping Li Yan Jiang Hui-Jun Li
author_sort	Lingchang Meng
title	miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
title_short	miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
title_full	miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
title_fullStr	miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
title_full_unstemmed	miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
title_sort	mir122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/9f5f733cc6914f77b87c7c4ef60d5273
work_keys_str_mv	AT lingchangmeng mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT qiaoleiwang mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT laiwang mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT zhenzhao mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT guizhongxin mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT zuguozheng mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT pingzhou mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT pingli mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT yanjiang mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease AT huijunli mir122controlledallinonenanoplatformforinsitutheranosticofdruginducedliverinjurybyvisualizationimagingguidedondemanddrugrelease
_version_	1718429913882558464

miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release

Ejemplares similares